Quest Diagnostics

Drug Sponsors

Biotechnology Industry Organization to become Biotechnology Innovation Organization

Friday, June 19, 2015 12:16 PM

Biotechnology Industry Organization will soon change its name to the Biotechnology Innovation Organization.

More... »


Abbott will vote its Mylan shares in favor of Mylan's proposed acquisition of Perrigo

Wednesday, June 17, 2015 09:51 AM

Abbott has confirmed its continued support for Mylan's growth strategy by stating its intent to vote its 14.5% stake in Mylan in favor of Mylan's proposed acquisition of Perrigo.

More... »


Medivir restructures, partners with GVK BIO

Wednesday, June 17, 2015 09:48 AM

Medivir, a research based pharmaceutical company based in Sweden, has announced a reorganization within its Discovery Research department, increasing its focus within the core areas of oncology and infectious diseases, and a partnership with GVK Biosciences Private (GVK BIO) of Hyderabad in India, designed to deliver enhanced efficiency and quality within its portfolio of research projects while over time reducing overall research costs and enhancing future cost flexibility.

More... »

GSK launches Altius Institute for Biomedical Sciences

Wednesday, June 17, 2015 09:25 AM

GlaxoSmithKline is launching the Altius Institute for Biomedical Sciences, an independent, nonprofit research institute in Seattle. Altius will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions in health and disease. GSK expects to capitalize on rapid progress in understanding gene control to select and validate better drug targets, and to accelerate many key aspects of developing new medicines.

More... »

Roswell Park Cancer Institute spins out new company OmniSeq

Friday, June 12, 2015 12:13 PM

OmniSeq has officially begun its spin out from Roswell Park Cancer Institute (RPCI) and will immediately begin commercializing its suite of innovative products that support a physician-driven, collaborative approach to genomic diagnostics—matching cancer patients to therapies tailored specifically to them. Collectively known as OmniSeq Precision Medicine Technology, OmniSeq provides oncology groups, hospitals and healthcare systems with the first-ever fusion of clinical genomics and a comprehensive information technology solution that provides easy access to actionable insights about their patient’s condition and available treatment options. Like Roswell Park, OmniSeq is based in Buffalo, N.Y.

More... »

Altan Pharma acquires Spain-based pharma GES Group

Friday, June 12, 2015 10:33 AM

Altan Pharma, an Irish specialty pharmaceutical company has acquired a privately held group of Spanish companies, The GES Group. The GES Group develops, manufactures and markets specialty injectable drugs. GES, headquartered in Spain, is comprised of three operating companies: GES Genéricos Españoles Laboratorio, Genfarma Laboratorio and Biomendi. 

More... »

GlobeImmune restructures, cuts “majority” of workforce

Thursday, June 11, 2015 12:03 PM

GlobeImmune, a biopharmaceutical company based in Louisville, Colo., will eliminate the majority of positions in its workforce. This is not expected to have an impact on ongoing clinical trials being conducted by its collaborators in oncology and hepatitis B.

More... »

Panasonic Healthcare acquires Bayer Diabetes

Wednesday, June 10, 2015 11:18 AM

Panasonic Healthcare Holdings (PHCHD), based in Tokyo, has inked an agreement to acquire Bayer Diabetes Care (BDC) for $1.2 billion to create a global diabetes care solutions business. BDC is a provider of blood glucose monitoring systems to people with diabetes and healthcare professionals around the world. It was formed as a business unit within Bayer and is present in more than 125 countries. It generated sales of $1 billion in 2014.

More... »

With buyout option, Celgene collaborates with Lycera

Wednesday, June 10, 2015 11:17 AM

Lycera, a U.S.-based privately held biopharmaceutical company developing breakthrough immune modulatory medicines, has formed an exclusive global collaboration with Celgene to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases.

More... »

Teva rebuts Mylan chairman’s letter

Wednesday, June 10, 2015 11:13 AM

Erez Vigodman, Teva’s president and CEO, has responded to the June 1 letter by Mylan’s executive chairman Robert J. Coury. Vigodman addresses Courey’s accusations about Teva’s hostile takeover of Mylan and the lack of information available to stakeholders.

More... »

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs